Chinese Biopharma Hits $41.5 Billion in Licensing Deals US Takes Half
In 2024, Chinese biopharma companies reached a five-year high in licensing agreements, totaling $41.5 billion, a 66% increase compared to 2020. Notably, 50% of these deals were with U.S. pharmaceutical firms, showcasing China's growing influence in the global biopharma landscape.
According to GlobalData Pharma Intelligence, government investments have accelerated faster, more affordable clinical trials, boosting the appeal of Chinese drug innovations. Among the major deals, Merck licensed LaNova Medicines' PD-1/VEGF bispecific antibody LM-299 for $3.28 billion, while Novartis entered a $4.35 billion agreement with Shanghai Argo Biopharmaceutical for an RNA-based cardiovascular treatment.
Oncology, immunology, and metabolic disorders dominated the market, accounting for $22.2 billion in licensing value. Advanced therapies like monoclonal antibodies ($11.3 billion) and antibody-drug conjugates (ADCs, $10 billion) were also highly sought after.
While licensing surged, mergers and acquisitions declined, with licensing emerging as a cost-effective way for global companies to access innovative drugs. Analysts warn, however, that regulatory shifts and potential trade barriers could disrupt these cross-border partnerships, impacting drug costs and global supply chains.
2026-10-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Trump Tariff "Boomerang": $2.5 Billion Polysilicon Factory Faces Shutdown Crisis
-
China’s Chemical Time Bomb Just Got a Legal Fuse: The New Law That Could Save Thousands of Lives
-
U.S. Strikes Three Iranian Tankers as “Tanker-for-Tanker” Escalation Raises Chemical Shipping Risk
-
Panama Canal Delays Deeper Draft Cut, but Transit Capacity Is Still Tightening
-
Hormuz Closes, Paint Feels It First: How a Barrel of Oil Rewrites the Cost of Every Barrel of Coatings
-
Saudi Energy Facilities Hit as Middle East Feedstock Risk Spreads Toward the Red Sea
-
China Methanol Futures Hit Limit-Up as More Than 60% of Middle East Capacity Remains Offline
-
“Fake Fame” in a Forgotten Dock: Chinese Authorities Bust $100,000 Counterfeit Building Materials Ring
-
Asian Paints Dives Deeper into the Desert: Unveils Second UAE Plant to Dominate GCC Coatings Market
-
From Rust to Recharge: Novonix Ignites America’s Graphite Independence with Twin Mega-Plants in Chattanooga
Recommend Reading
-
Middle East Conflict Pushes Up Oil Prices as More Than 100 Chemical Raw Materials Rise in Concentration
-
Redwall Raises Prices by as Much as 80%, Songwon Launches Global Increases, and Chemical Companies Are Collectively Passing On Costs
-
BASF Raises European NPG and HDO Prices by Up to €300/Tonne as Costs Climb
-
End of an Era: KDC/One to Close 150-Year-Old Somerset Cosmetics Factory as Production Shifts to Scotland
-
Global Chemical Exports Are Freezing in 2026
-
Oxalic Acid: Acidity (pKa), Sources, and Kidney Stone Risk
-
What is a Surfactant? (Definition, Types, and How They Work)
-
Sulfate Ammonium Prices Continue to Rise in China Over the Past Ten Days (3.7-3.17)
-
Geopolitical Tensions in the Middle East Escalate, Leading to a Rebound in Isooctanol Prices
-
Marginal Improvement: Shandong n-butanol Market Shows Signs of Recovery